Q BioMed Announces Full Settlement of All Convertible Debt

Company Closes Financial Year End With No Outstanding Convertible or Loan Debt NEW YORK, December 5, 2017 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration Company, announced today that all convertible notes and loans have been settled in full,...

Q Biomed looks to dust off shelved cancer pain drug

Denis Corin has spent the last 13 years in the biopharmaceutical industry watching and learning from scientists and companies that fail. “I’ve seen so many promising and innovative young technologies really struggle along or die on the vine because they’re run by...

Q BioMed Inc. Closes $3,050,390 Equity Financing

Funding Provides Capital to Meet Near Term Milestones and CatalystsNEW YORK, August 2, 2017 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO) is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors...